Edwards Lifesciences Corporation revealed new data to support its SAPIEN 3 valve which demonstrated sustained health status advantages for patients with severe aortic stenosis (AS), specifically when used on those with low surgical risk.
Evidence of this was collated through Edwards’ PARTNER 3 Trial, which observed roughly 1,000 patients over a one-year period. The study showed a significant improvement in patients’ health, physical and mental wellbeing following treatment using TAVR, the SAPIEN 3 valve, or SAVR.
Results of the study were published in the Journal of the American College of Cardiology, and presented at the 31st Transcatheter Cardiovascular Therapeutics (TCT) annual symposium of the Cardiovascular Research Foundation.
The director of interventional cardiology research and Lahey Hospital and Medical Centre, Suzanne J. Baron, M.D., M.Sc., said: “Taken together with the clinical outcomes of the PARTNER 3 Trial, these health status findings further support the use of TAVR in patients with severe aortic stenosis at low surgical risk.”
Edwards’ corporate vice president of transcatheter aortic valve replacement, Larry Wood, said: “SAPIEN 3 TAVR is a proven technology with demonstrated clinical and health status superiority for these low-risk patients. This study further demonstrates both early and late benefits of TAVR that are important to patients who lead active, productive lives."